Data are generally consistent for the selected Phase 3 dose level, including a 55% ORR, which is an approximately 2-fold increase compared to historical pembrolizumab monotherapy data. Patients ...

Lenvatinib plus pembrolizumab has improved survival rates for patients with intermediate-stage hepatocellular cancer, ...

Fecal microbiota transplantation has significantly improved progression-free survival in patients with metastatic renal cell ...

Citius Pharmaceuticals (CTXR) and Citius Oncology (CTOR) announced “promising” preliminary results from an ongoing ...

Patients with Lung Cancer who had Exhausted All Other Treatment Options Achieved Prolonged Progression Free Survival Following Treatment with NUC-3373 plus Docetaxel EDINBURGH, United Kingdom, (GLOBE ...

Editor's note: This story has been revised to include additional comments. CHICAGO — In patients with stage IVB anaplastic ...

Updated findings from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study (NCT04221945) show the survival advantages of ...

Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and ...

In a real-world diverse population of patients with early triple-negative breast cancer (TNBC), 34% of patients who received ...

周一，JMP Securities给予Summit Therapeutics plc (NASDAQ:SMMT)一个"市场表现优于大盘"的评级，目标价为$32.00。这一新的覆盖反映了对该公司最近从传染病转向肿瘤学的战略转变持积极看法。 这家生物制药公司在2022年进行了战略转型，从Akeso引进了ivonescimab，这是一种PD-1 x VEGF双特异性抗体。这笔交易包括5亿美元的预付款和高 ...

该公司的市值为7642万美元，反映了其在生物技术板块的当前估值。尽管临床试验结果积极，但InvestingPro数据显示，IO Biotech尚未盈利，截至2023年第二季度的过去12个月调整后营业收入为-9340万美元。这对于大量投资于研发的早期生物技术公司来说并不罕见。

In an interview with Targeted Oncology, Peter Schmid, MD, PhD, discussed the results from the phase 3 KEYNOTE-522 trial.